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THE development of procedures to isolate large num-bers of purified human pancreatic islet cells has made 
it possible to initiate a new phase of clinical trials in 
pancreatic islet transplantation for treatment of type I 
diabetes. l -4 Although nonspecific immunosuppressive 
agents have been instrumental in controlling alloreactivity 
to transplanted islet cells, rejection still occurs and is a 
major limitation to islet transplantation.5.ft The induction 
of donor-specific transplantation across a species barrier. 
using bone marrow stem cells to produce chimerism and 
induce donor-specific transplantation tolerance. has been 
suggested as a potential approach to prevent rejection of 
transplanted cells. 7- 9 The purpose of this study was to 
determine whether long-term acceptance and function of 
xenogeneic pancreatic islet grafts could be achieved in 
fully xenogeneic chimeras. 
MATERIALS AND METHODS 
Fully xenogeneic chimeras were prepared by transplantation of 40 
x 100 non-TCD Wistar Furth bone marrow cells into C57BUIO Sn 
mouse recipients conditioned with 950 R rads total body irradia-
tion before transplantation. Animals were typed for chimerism at 
4 weeks and made diabetic by intravenous injection of streptozo-
tocin (165 mgikg). Only mice with a plasma glucose concentration 
exceeding 300 mgidL for I week were used as islet recipients. Rat 
pancreatic islets were obtained by the modification of an auto-
mated method for isolation of human pancreatic islet cells and 
purified by the COBE cell separator with Euro-Collins-Ficoll 
gradients. 4 Eight hundred donor-specific Wistar Furth or third-
party F344 rat pancreatic islets were implanted beneath renal 
capsule of diabetic chimeras. Nonfasting blood glucose levels 
were determined daily to check function. 
RESULTS AND DISCUSSION 
The survival of the donor-specific Wistar Furth rat pancre-
atic islet xenografts was significantly prolonged (mean 
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survival time> 120 days), while major histocompatability 
complex disparate third-party F344 islets were rapidly 
rejected (mean survival time = 8 days). The donor-specific 
grafts were functional and maintained the normoglycemic 
state in chimeras. This study demonstrated that long-term 
survival and function of donor-specific pancreatic islet 
xenografts can be obtained in fully xenogeneic chimeras. 
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